Projection Mapping Showcase of "YOASOBI / 'Idol’” Premiered Saturday, December 14!
20.1.2025 04:14:00 CET | Business Wire | Press release
~ Over 450,000 Visitors Have Experienced "TOKYO Night & Light" ~
The Tokyo Metropolitan Government has been hosting year-round projection mapping displays at the iconic Tokyo Metropolitan Government Building (No. 1 Building). These displays use light and sound to create vibrant and diverse works of art, transforming the landmark into a new tourism resource that illuminates Tokyo’s nightscape. The event began in February of 2024 and has been visited by approximately 450,000 people to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107191600/en/
YOASOBI / 'Idol’ (Photo: Business Wire)
Recently, a new projection mapping work featuring YOASOBI's globally acclaimed song "Idol" premiered on Saturday, December 14. The opening day saw a large number of visitors from both Japan and abroad, creating an exciting atmosphere befitting such a popular attraction.
Feedback from attendees included comments such as, "I came to Japan as a tourist, and after seeing the weekday version, I wanted to see the weekend version as well, so I came back," "This is the most powerful projection mapping I've ever seen -- it was truly moving," and "YOASOBI's new content had a retro vibe, which I really enjoyed. I don’t think you’d see something like this very often overseas.”
Visitors can enjoy projection mapping videos created by renowned domestic and international creators, who have been highly praised at international competitions. This event is quickly evolving into one of Tokyo's must-visit tourist attractions. With its exceptional artistry, cutting-edge technology, and world-class content, this "new nighttime tourism hotspot that lights up Tokyo's nights" is one to watch.
Overview of the Work | YOASOBI / "Idol"
The song "Idol" by YOASOBI, which gained widespread attention as the theme song for an anime, is a masterpiece that blends rhythmic and vibrant elements with themes of uncertainty and inner conflict. The projection mapping display brings the emotional nuances of this song to life, offering an immersive visual and auditory experience.
Creator: Yukihiro Oka (Japan)
* Please visit our website for the screening schedule.
https://tokyoprojectionmappingproject.jp/en/
About the song
YOASOBI’s hit song "Idol" broke records by surpassing 800 million cumulative streaming plays in the shortest time ever. It topped several major global charts, including the U.S. Billboard Global Chart “Global Excl. U.S.,” Apple Music’s “Top 100: Global,” and YouTube Music Charts TOP 100 Songs Global, setting unprecedented milestones in J-POP history.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107191600/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom